Crossmark

Antidepressant drug switching in the Swiss population with a focus on Escitalopram and drugs with pharmacogenetic dosing guidelines: a drug utilization study using claims data

Crossref DOI link: https://doi.org/10.1038/s41397-025-00382-1

Published Online: 2025-08-08

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Roth, M. M.

Meier, C. R.

Huber, C. A.

Meyer zu Schwabedissen, H. E.

Allemann, S. https://orcid.org/0000-0003-4067-9401
Schneider, C.
License Information

Text and Data Mining valid from 2025-08-08

Version of Record valid from 2025-08-08
More Information

Article History

Received: 20 December 2024

Revised: 7 July 2025

Accepted: 16 July 2025

First Online: 8 August 2025

Competing interests

: The authors declare no competing interests.

: According to article 22 of the Swiss Federal Law on data protection ethics approval was not necessary, as the study was retrospective and used anonymized data [].

Document is current

Any future updates will be listed below